Long non-coding RNAs in prostate cancer: Biological and clinical implications

Rajdeep Das, Felix Y. Feng, Luke A. Selth

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Prostate cancer (PCa) is a major health issue in the Western world. Current clinical imperatives for this disease include better stratification of indolent versus aggressive disease to enable improved patient management, as well as the identification of more effective therapies for the prevention and treatment of metastatic and therapy-resistant PCa. The advent of next-generation transcriptomics led to the identification of an important class of molecules, long non-coding RNAs (lncRNAs). LncRNAs have critical functions in normal physiology, but their dysregulation has also been implicated in the development and progression of a variety of cancers, including PCa. Importantly, a subset of lncRNAs are highly prostate-specific, suggesting potential for utility as both biomarkers and therapeutic targets. In this review, we summarise the biology of lncRNAs and their mechanisms of action in the development and progression of prostate cancer. Additionally, we cast a critical eye over the potential for this class of molecules to impact on clinical practice.

Original languageEnglish
Pages (from-to)142-152
Number of pages11
Publication statusPublished - 15 Jan 2019
Externally publishedYes


  • Biomarker
  • lncRNAs
  • Long non-coding RNAs
  • Prostate cancer
  • Therapy


Dive into the research topics of 'Long non-coding RNAs in prostate cancer: Biological and clinical implications'. Together they form a unique fingerprint.

Cite this